Technical information and posters

Basic Information
- G-001 Glass Transition Temperature of Cellulose Derivatives by TMA Method
- G-002 Film Properties of HPMC and MC
- G-003 Molecular Weight and Degree of Polymerization of HPMC
- G-004 Cloud Points of Aqueous Solution of Water-Soluble Cellulose Ethers
- G-005 Equilibrium Moisture Content of Water-Soluble Cellulose Ethers
- G-006 Calculation of Molar Substitution from Chemical Analysis
- G-007 Stability of Cellulose Products
- G-009 Density of Solution for Viscosity Measurement
- G-011 Film and Other Properties of Low-Viscosity Grade Cellulose Derivatives
- G-015 Solubility of Cellulose Derivatives in Mixed Organic Solvents
- G-016 Oxygen Permeability of Low-Viscosity Grade Cellulose Derivatives
- G-017 Glass Transition Temperature of Cellulose Derivatives by DSC Method
- G-018 Glass transition temperature of Hypromellose
- G-019 Peroxide in Pharmaceutical Excipients
Applications
- G-008 Maximum Pharmaceutical Daily Dose Approved in Japan
- G-010 Formulation of McIlvaine's Buffer and Clark-Lubs' Buffer Solutions
- G-012 Biological Oxygen Demand of Methylcellulose (MC) and Hypromellose (HPMC)
- G-014 Test Fluids for Disintegration and Dissolution Tests for Enteric-Coated Tablets
- G-020 Evaluation of Anthrone Reaction as an Assay Method for HME CleanerPlus in Cleaning Validation

PageTop

Basic information
- A-007 Molecular weight of Shin-Etsu AQOAT^® (HPMCAS)
  Analyzed by GPC-MALLS
- A-011 Dust explosivity and electrostaticity of Shin-Etsu AQOAT^®
- A-016 Film solubility of Shin-Etsu AQOAT^® (HPMCAS) in various buffers
- A-020 Bibliography 1/ HPMCAS (Shin-Etsu AQOAT^®)
  Until March 2011
- A-046 Bibliography 2/ HPMCAS (Shin-Etsu AQOAT^®)
  From April 2011 to December 2015
- A-026 Particle size measurement by laser diffraction method
  Analyzed by HELOS/KF + RODOS
- A-027 Stability of Shin-Etsu AQOAT^® in various organic solvents
- A-030 Toxicological information of hypromellose acetate succinate
- A-035 Solubility of Shin-Etsu AQOAT^® in mixed organic solvents
- A-052 Stability of Shin-Etsu AQOAT^® under humid storage conditions
- A-054 IR spectrums of HPMCP and Shin-Etsu AQOAT^®
- A-058 Solution preparation of HPMCP and Shin-Etsu AQOAT^®
  Solution preparation with ethanol and water
- A-064 Concentration viscosity curve of Shin-Etsu AQOAT^®
  Viscosity and rheological properties with several organic solvents
Coating
- A-001 Preparation of coating solution of aqueous dispersion using Shin-Etsu AQOAT^®
- A-002 Aqueous dispersion coating using Shin-Etsu AQOAT^® -Tablet batch size of 5-100 kg
  Parameters comparison with scale-up
- A-003 Aqueous dispersion coating using Shin-Etsu AQOAT^®-Granule batch size of 1.5 kg
- A-006 Aqueous dispersion coating using Shin-Etsu AQOAT^® -Tablet batch size of 300 g using small equipment
- A-004 Enteric coating with Shin-Etsu AQOAT^® by using water-ethanol solution
  Coating example for pellets with solvent system
- A-005 Minimum film formation temperature of Shin-Etsu AQOAT^® 1
  Influence of grades
- A-047 Minimum film formation temperature of Shin-Etsu AQOAT^® 2
  Influence of plasticizer
- A-008 Aqueous(Ammonia-neutralized-method) coating with Shin-Etsu AQOAT^® 1
  Solution and film properties
- A-012 Aqueous(Ammonia-neutralized-method) coating with Shin-Etsu AQOAT^® 2
  Examples of coating applications
- A-013 Aqueous(Ammonia-neutralized-method) coating with Shin-Etsu AQOAT^® 3
  Stability of the coated tablets
- A-014 Influence of alcohol on gastric resistance of coated tablets with Shin-Etsu AQOAT^®
- A-015 Enteric-coated pellets using Shin-Etsu AQOAT^® to be incorporated in tablets
  Comparison with other enteric coating substance on processing
- A-019 Explosivity risk assessment of the dry coating process using Shin-Etsu AQOAT^®
- A-021 Solubility of Shin-Etsu AQOAT^® in alkali solutions
  For cleaning media after coating operations
- A-022 Application of Shin-Etsu AQOAT^® to enteric coating of pancreatin pellets 1
  Influence of drying process to enzymes
- A-023 Application of Shin-Etsu AQOAT^® to enteric coating of pancreatin pellets 2
  Process optimization and scale up
- A-024 Innovative aqueous coating using a dual-feed concentric nozzle with Shin-Etsu AQOAT^®
- A-029 Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT^®
- A-031 Enteric coating of omeprazole granules using Shin-Etsu AQOAT^®
  Application to acid sensitive drugs and comparison to other coating substances
- A-033 Granule coating using Shin-Etsu AQOAT^® 1
  Aqueous dispersion coating by bottom spray (wurster) method
- A-038 Granule coating using Shin-Etsu AQOAT^® 2 -Batch size of 10 kg
  Aqueous dispersion coating by bottom spray (wurster) method
- A-036 Taste masked coated pellets into ODT formulation
  Taste masking coating by the combination with water soluble polymer
- A-037 Partially neutralized coating technique using Shin-Etsu AQOAT^® 1
  Improved coating method with ammonia
- A-049 Partially neutralized coating technique using Shin-Etsu AQOAT^® 2
  Improved coating method with L-Arginine
- A-039 Stability of Shin-Etsu AQOAT^® ammonia-neutralized solution
- A-040 Dry powder coating using Shin-Etsu AQOAT^® - Film formation properties
  Optimization of formulation
- A-041 Dry powder coating using Shin-Etsu AQOAT^® 1
  Pellet coating by wurster method (GPCG-1)
- A-042 Dry powder coating using Shin-Etsu AQOAT^® 2
  Tablet coating using ventilated pan coater (HC-130)
- A-043 Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT^® 1
  By aqueous dispersion method
- A-062 Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT^® 2
  By aqueous dispersion and partially neutralized method
- A-044 Aqueous fine particle coating with angled spray 1
  Ammonia neutralized coating by the combination with METOLOSE^® SM-4
- A-045 Aqueous and organic fine particle coating with angled spray 2
  Evaluation of dissolution from coated pellets
- A-048 Aqueous and organic fine particle coating with angled spray 3
  Evaluation of taste masking effect
- A-053 Aqueous enteric coating using Shin-Etsu AQOAT^® for mini-tablets
- A-055 Aqueous formulation of Shin-Etsu AQOAT^® containing an amino acid as a heat resistance stabilizer
  Comparison of process parameters on different coating equipments
- A-056 Mini-tablets coating using Shin-Etsu AQOAT^®
  Comparison of pan coater or fluid bed coating equipments
- A-057 Aqueous dispersion coating with Shin-Etsu AQOAT^® using triacetin as an alternative plasticizer
- A-059 Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT^®
  Comparison with other enteric coating substance on pellets
- A-060 Pellets coating using Shin-Etsu AQOAT^®
  Comparative study of various coating methods
- A-061 Taste masking coating using Shin-Etsu AQOAT^®
  Evaluation of dissolved API by HPLC
- A-063 Taste masking coating using Shin-Etsu AQOAT^® and Pharmacoat^® with controlled release
  Coating for mini-tablets by ammonia neutralized coating
- A-065 Partly neutralized coating using with Shin-Etsu AQOAT^® with L-arginine
  Influence of grades to suitable amount of amino acid
- A-068 Partly neutralized coating using with Shin-Etsu AQOAT^® with ammonia
  Scale up study
- A-075 Complete dry coating technique of Shin-Etsu AQOAT^® using centrifugal granultor
Solid dispersion
- A-009 Stability of Shin-Etsu AQOAT^® at high Temperatures 1
  Stability at 80- 150 oC
- A-010 Stability of Shin-Etsu AQOAT^® at high Temperatures 2
  Stability at 150- 180 oC
- A-017 Stability of Shin-Etsu AQOAT^® at hot-melt extrusion
- A-018 Solid dispersions using Shin-Etsu AQOAT^® (HPMCAS) by hot-melt extrusion
  Evaluation with nifedipine
- A-028 Application of Shin-Etsu AQOAT^® in solid dispersion 1
  Formulation of nifedipine solid dispersion by spray granulation
- A-032 Application of Shin-Etsu AQOAT^® in solid dispersion 2
  Influence of substitution level to dissolution and properties
- A-034 Solid dispersion of ibuprofen with Shin-Etsu AQOAT^®
  By hot-melt extrusion
- A-051 Solid dispersion using Shin-Etsu AQOAT^®-Preparation by HME and downstream processing
  Nifedipine solid dispersion by hot-melt extrusion into MUPS tablets
- A-066 Roller compaction of spray dried dispersion 1
  Basic study on granules properties and compression into tablets
- A-067 Formulation of hot-melt extruded solid dispersions with Shin-Etsu AQOAT^®
  Downstream processing study by milling
- A-071 Impact of process parameters on spray drying to solid dispersion particle
- A-072 Direct Compression of Spray Dried Dispersion
- A-073 Mechanical Properties of Hot Melt Extruded Amorphous Solid Dispersions with Shin-Etsu AQOAT®
- A-074 Dissolution Technology Using HPMCAS Solid Dispersion Targeting the Upper Small Intestinal
Others
- A-069 3D printing tablets with Shin-Etsu AQOAT^®
- A-070 Application of Shin-Etsu AQOAT^® in extended release matrix tablet formulation

PageTop

Basic Information
- L-001 Particle Size Measurement by Laser Diffraction Method
- L-002 Swelling of L-HPC in Various Test Media
- L-004 Dust Explosivity and Electrostaticity of L-HPC
- L-007 Bibliography / L-HPC
- L-013 Toxicological information of Low-substituted hydroxypropyl cellulose
- L-017 Particle size analysis of L-HPC with various particle size analyzers
- L-025 Bibliography 2 / L-HPC
- L-033 IR spectrums of L-HPC and SmartEx^®
- L-041 Water Absorption of L-HPC

Applications
- L-003 Formulation Example: Ginkgo Extract Tablets Using L-HPC
- L-005 Dry Compaction Using L-HPC
- L-006 Bilayer Tablets Using L-HPC and METOLOSE^® SR
- L-008 Orally Disintegrating Tablets Using L-HPC
- L-009 CapsuleFiller
- L-010 Roller compaction using L-HPC
- L-011 Pellet extrusion - spheronization using L-HPC
- L-012 Differences in wet granulation processing using L-HPC
- L-014 Effects of the added water quantity to the tablet properties at wet granulation process with L-HPC
- L-015 Pellets preparation by drug layering using L-HPC
- L-016 Orally disintegrating tablets using L-HPC(NBD grades)
- L-018 Water Binding Capability of L-HPC in Wet Granulation
- L-019 Comparative Study of Various L-HPC for Paracetamol 500 mg Tablets-Particle Attributes-
- L-020 Comparative study of various L-HPC for paracetamol 500 mg tablets-Hydroxypropyl content -
- L-021 Comparative Study of Various L-HPC for Paracetamol 500 mg Tablets-Internal Addition and Particle Attributes-
- L-022 Comparative Study of Various L-HPC for Paracetamol 500 mg Tablets-Roller compaction-
- L-023 Improvement of Dissolution from Tablet Containing Herbal Medicine using L-HPC
- L-024 Minitablets using L-HPC
- L-027 Super-High Speed Direct Compression using L-HPC NBD
- L-028 Twin screw granulation using L-HPC
- L-029 The Effect of a Glidant on L-HPC
- L-030 The Effect of a Glidant on L-HPC for dry granulation
- L-031 Change of swelling performance of disintegrants after wet granulation
- L-032 Influence of tablet shape on capping tendency
- L-037 Roller compaction of spray dried dispersion 1: Basic study on granules properties and compression into tablets
- L-038 Interaction with L-HPC and Vitamins
- L-039 Application of L-HPC and PHARMACOAT^® in twin screw granulation for continuous manufacturing
- L-040 Suitability of L-HPC and PHARMACOAT^® in twin screw wet granulation
  Significance and synergistic effect
- L-042 Effect of L-HPC 31 in drug layering

PageTop

Basic Information
- H-004 Film Solubility of HPMCP in Various Buffers
- H-005 Hydrolysis of HPMCP in Water-Ethanol Solution
- H-007 Residual Solvent in Water/Ethanol HP-55 Tablet Coating
- H-008 Molecular Weight of HPMCP
- H-009 Toxicological information of hypromellose phthalate
- H-010 Solubility of HPMCP in mixed organic solvents
- H-011 Film Solubility of Mixed HPMCP
- H-016 Stability of HPMCP under Humid Storage Conditions
- H-017 IR spectrums of HPMCP and Shin-Etsu AQOAT^®
- H-019 Solution preparation of HPMCP and Shin-Etsu AQOAT^®
Applications
- H-001 HPMCP - Typical Coating Conditions for Tablets
- H-002 HPMCP - Typical Coating Conditions for Granules (1)
- H-003 HPMCP - Typical Coating Conditions for Granules (2)
- H-006 Enteric Coating of Hard Gelatin Capsules Using HPMCP
- H-012 Solvent Coating for Fine Particle with Angled Spray
- H-013 Dissolution Behavior of Coated Fine Particles by Aqueous and Solvent Coating
- H-014 Taste Masking of Coated Fine Particles by Aqueous and Solvent Coating
- H-015 Stability of HPMCP Coated Tablets
- H-018 Enteric Coating of Soft Gelatin Capsules with Hypromellose Phthalate (HPMCP)
- H-020 Application of HPMCP and SmartEx^® in the development of MUPS-ODT for Lansoprazole 15 mg
- H-021 Itraconazole 65 mg capsule using HPMCP by solid dispersion approach
- H-022 Application of HPMCP of rabeprazole sodium delayed release tablet by organic enteric coating
- H-023 Application of Hypromellose Phthalate in Extended Release (ER) Matrix Tablet formulation
- H-024 Neutralization effect on Hypromellose Phthalate using different alkalizer

PageTop

Basic Information
- SR-013 Particle Size Distribution of METOLOSE^® SR
- SR-010 Particle Size Analysis of METOLOSE^® SR with Various Laser Analyzers
Applications
- SR-001 Comparison between Direct Compression and Wet Granulation in Hydrophilic Matrix Tablets Using METOLOSE^® SR
- SR-003 Solvent Selection in Wet Granulation for Hydrophilic Matrix Tablets Using METOLOSE^® SR
- SR-002 Sustained Release of Naproxen Using METOLOSE^® SR
- SR-004 Formulation Example: Lithium Carbonate Extended-Release Tablet Using METOLOSE^® SR
- SR-005 Bilayer Tablets Using L-HPC and METOLOSE^® SR
- SR-006 A Study on the Robustness of the Wet Granulation Process to Prepare Metformin HCl Extended-Release Matrix Tablets using METOLOSE^® 90SH-15000SR
- SR-007 The effect of the solubility of APIs on the dissolution profiles of hydrophilic matrix tablets containing METOLOSE^® SR
- SR-008 The effect of CMCNa on the dissolution profiles of hydrophilic matrix tablets containing METOLOSE^® SR
- SR-009 QbD (Quality by design) approach to the formulation of hydrophilic matrix tablets using METOLOSE^® SR-Dipyridamole-
- SR-011 QbD (Quality by design) approach to the formulation of hydrophilic matrix tablets using METOLOSE^® SR-Metformin-
- SR-014 QbD (Quality by design) approach to the formulation of hydrophilic matrix tablets using METOLOSE^® SR-Paracetamol-
- SR-012 Comparative Study of Dissolutions from Matrix Tablets with METOLOSE^® SR by Different Preparation Methods
- SR-015 The Effect of a Glidant of Hydrophilic Matrix Tablets Containing METOLOSE^® SR
- SR-016 METOLOSE^® SR in 500 mg Metformin HCl Extended Release Tablets: Simulation of High Speed Compaction
- SR-017 Formulation of Paracetamol Bilayer Tablet (Dose: 650 mg)
- SR-018 Formulation of Metformin HCl Sustained Release Tablets
- SR-019 Coating Application of METOLOSE^® in Sustained Release (SR) Tablets
- SR-020 Coating application of METOLOSE^® in extended release pellet formulation
- SR-021 Impact of combination of METOLOSE® SR grades^® in Carbamazepine Extended Release (ER) Matrix Tablet formulation

PageTop

Basic Information
- M-001 Adjusting Viscosity by Blending Two Grades of METOLOSE^®
- M-004 Solubility of HPMC and MC (15 mPa•s) to Organic Solvents
- M-005 Toxicological information of Methylcellulose
- M-006 Toxicological information of Hypromellose
- M-008 IR spectrums of METOLOSE^® and Pharmacoat^®
Applications
- M-002 METOLOSE^® SM-4 for Pellet Film Coating
- M-003 Taste Masking of Fine Granules by METOLOSE^® SM-4 and an Acrylic Polymer
- M-007 High gloss coating formulation using METOLOSE^®

PageTop

Basic Information
- P-001 Growth of Microorganisms in Aqueous Solution of PHARMACOAT^®
- P-002 Stability of PHARMACOAT^® Solution in Sterilization
- P-003 Filtration of PHARMACOAT^® Solutions
- P-004 Solubility of PHARMACOAT^® 606 in Alcohol-Water Mixtures
- P-005 Effect of Moisture Content on the Mechanical Properties of Cast HPMC Films
- P-008 Effect of plasticizers and other additives on the mechanical properties of cast hypromellose films
- P-014 Dissolution behavior of various lower viscosity grades
- P-015 IR spectrums of METOLOSE^®and Pharmacoat^®
- P-016 Solubility of PHARMACOAT^® 606 in Acetone/Water Mixtures
Applications
- P-006 Color Coating with PHARMACOAT^®
- P-007 Timed-release Coating with PHARMACOAT^® and Shin-Etsu AQOAT^® for Taste-masking Effect
- P-018 Taste masking coating using Shin-Etsu AQOAT^® and Pharmacoat^® with controlled release
- P-009 An organic coating method with Pharmacoat^® -With mixed solvent of high content of ethanol and water-
- P-010 Application of Pharmacoat^® (Hypromellose, HPMC) as a carrier in solid dispersion
- P-011 A coating technique for high-friability tablets using Pharmacoat^®
- P-012 An advanced coating formulation with PVA and HPMC
- P-013 Coating Formulation for Logo Tablets
- P-017 Comparative Study of Wet Granulation Binders
- P-019 Acid resistance coating using PHARMACOAT^® and sodium alginate
- P-020 Coating Formulation for Tablet Printing

PageTop

SE-001 Super-High Speed Direct Compression using SmartEx^®
SE-002 IR spectrums of L-HPC and SmartEx^®
SE-003 Tablet Weight Deviation and Content Uniformity of Tablets Prepared by Direct Compression Using SmartEx^®
SE-004 Disintegration, Tablet Weight Deviation and Content Uniformity of Tablets Prepared by Direct Compression Using SmartEx^®
SE-005 High API Dose Tablet with SmartEx^® and Additional L-HPC
SE-006 Stability of Ibprofen OD tablets using SmartEx^®
SE-007 Application of HPMCP and SmartEx^® in the development of MUPS-ODT for Lansoprazole 15 mg

PageTop

PBP16-1 Functional Cellulose Derivatives for Mini Tablets

PageTop

AAPS16-1 The study on swelling properties of various L-HPC
AAPS16-2 Super-High Speed Direct Compression Using SmartEx^®
AAPS16-3 Improvement of Drug Release from Hard Capsules Using L-HPC as a Filler
AAPS16-4 Functional Cellulose Derivatives for Mini Tablets
AAPS16-5 Nifedipine Solid Dispersion Using AQOAT^® HPMCAS: Preparation by HME and Downstream Processing
AAPS16-6 Investigation of the Effect of Substituent Groups of HPMCAS on Drug Crystallization Inhibition
AAPS16-7 Physical Stability of Amorphous Solid Dispersion Prepared from Melt-Extrusion Process Using Hypromellose Acetate Succinate

PageTop

AAPS17-1 Direct Compaction of Hypromellose acetate succinate (HPMCAS) based amorphous solid dispersion prepared by hot melt extrusion technology
AAPS17-2 Particle shape analysis of L-HPC by dynamic image analysis and its influence on physical properties
AAPS17-3 Investigation of user friendly enteric coating formulation using hypromellose acetate succinate (HPMCAS)
AAPS17-4 The effect of substitution type and drying conditions on the physical properties of HPMC films
AAPS17-5 Content uniformity on the tablets prepared by direct compression
AAPS17-6 Enteric coating of mini tablets using AQOAT HPMCAS-process comparison between performed pan and wurster coating

PageTop

PBP18-1 Release of Itraconazole from HPMCAS solid dispersions
PBP18-2 Variation of metformin HCL quality and the effect on extended release matrix tablets

PageTop

EuPFi18-1 Taste masking coating of mini-tablets with cellulose derivertives: formulation and analytical challenges

PageTop

AAPS18-1 Advantage of various pellet coating techniques using hypromellose acetate succinate (HPMCAS)
AAPS18-2 Evaluation of HPMCAS-nifedipine solid dispersion by DSC, XRD and their hyphenated analysis
AAPS18-3 Development and evaluation of dry enteric coating approach for lansoprazole delayed release pellets using Hypromellose Acetate Succinate (HPMCAS)

PageTop

EuMe19 Partly Neutralized HPMCAS Coating Formulations - Assessment of Coagulation Temperature and MFFT

PageTop

GrCon19 Comparative Granulation of a Pharmaceutical IR formulation using different technology

PageTop

PS19-1 Evaluation of a new grade of highly-compressible methylcellulose for direct compression
PS19-2 A film coating formulation that has better performance for tablet printing
PS19-3 Application of Hypromellose Phthalate (HPMCP) and Smart-Ex in the development of multiple unit pellet system (MUPS) orally disintegrating tablet (ODT) for Lansoprazole 15mg

PageTop

EuPFi20 3D Printing with HPMCAS for Personalized Medicines

PageTop

PS20 Preparation of 3D printing tablets by fused deposition modeling using Shin-Etsu AQOAT^®

PageTop

PBP2022-1 Scalingup Aqueous Enteric Coating withHypromellose Acetate Succinate (HPMCAS)

PageTop

CRS2022-1 Application of Twin Screw Wet Granulation for the Formulation Development of Metformin HCl SR Tablets using Metolose ® 90SH 100000SR

PageTop

PS22-1 Downstream Processing of Itraconazole: HPMCAS Amorphous Solid Dispersion: From Hot Melt Extrudate to Tablet Using a Quality by Design Approach
PS22-2 Effect of Critical Material Attributes of Low substituted Hydroxypropyl Cellulose(L HPC) on Twin Screw Wet Granulation of Acetaminophen

PageTop

PS23-1 Dissolution Technology Using APMCAS Solid Dispersion Targeting the Upper Small Intestine
PS23-2 Effect of Different Neutralizers and their concentration on Enteric Coating of Hypromellose Phthalate (HPMCP HP-50) and Drug Release in Various pH
PS23-3 Application of Hypromellose Phthalate (HPMCP) for the development of Esomeprazole 20mg Multi Unit Pellet System (MUPS)
PS23-4 Double Action of HPMCAS as a Binder and Precipitation Inhibitor in ASD Tablets Prepared by Hot-Melt Extrusion
PS23-5 Development of hydroxypropyl methylcellulose(HPMC) based titanium dioxide (TiO2) free coating
PS23-6 Assessment of Stability and Drosion Behavior of ASDs by using VCM technique

PageTop

Technical information

General

Basic Information

Applications

Shin-Etsu AQOAT® (Hypromellose Acetate Succinate)

Basic information

Coating

Solid dispersion

Others

L-HPC (Low-substituted hydroxypropylcellulose)

Basic Information

Applications

HPMCP (Hypromellose Phthalate)

Basic Information

Applications

METOLOSE® SR

Basic Information

Applications

METOLOSE®

Basic Information

Applications

PHARMACOAT®

Basic Information

Applications

SmartEx®

Posters

PBP, 2016

AAPS, 2016

AAPS, 2017

PBP, 2018

EuPFi, 2018

AAPS, 2018

Eu. Meeting on Pharmaceutics, 2019

Granulation Conference, 2019

Pharm Sci 360, 2019

Eu. Paediatric Formulation Initiative 2020

Pharm Sci 360, 2020

PBP, 2022

CRS, 2022

Pharma Sci, 2022

Pharma Sci, 2023

Shin-Etsu AQOAT^® (Hypromellose Acetate Succinate)

METOLOSE^® SR

METOLOSE^®

PHARMACOAT^®

SmartEx^®

Eu. Paediatric Formulation Initiative　2020